NCT07265674
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07265674
Title A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer (Beacon-BTC)
Acronym Beacon-BTC
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors J-Pharma Co., Ltd.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.